ZURNAI (AUTOINJECTOR)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZURNAI (AUTOINJECTOR) (ZURNAI (AUTOINJECTOR)).
Hyaluronidase degradation of interstitial hyaluronan, increasing tissue permeability to facilitate fluid dispersion and drug absorption.
| Metabolism | Primarily hepatic via proteolysis; renally excreted as small peptides. |
| Excretion | Primarily renal excretion as unchanged drug or acetylated metabolite (about 70-80% of the dose). A small fraction undergoes biliary/fecal excretion (<10%). |
| Half-life | Terminal elimination half-life is approximately 2.5 hours in adults. In renal impairment, half-life may extend up to 6 hours, necessitating dosing adjustments. |
| Protein binding | Approximately 20-30% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | Volume of distribution (Vd) is approximately 2-4 L/kg, suggesting extensive tissue distribution beyond plasma volume. |
| Bioavailability | Subcutaneous injection: Approximately 100% (complete bioavailability). |
| Onset of Action | Subcutaneous: Muscarinic effects (e.g., sweating) appear within 15-30 minutes; clinical therapeutic effect (e.g., cognitive improvement) may require 4-6 weeks of chronic dosing. |
| Duration of Action | Subcutaneous: Duration of peripheral muscarinic effects (e.g., increased secretions) is 3-6 hours. Cognitive benefits from chronic therapy persist as long as dosing continues. |
| Molecular Weight | 140000 |
Epinephrine 0.3 mg intramuscularly (into anterolateral thigh) every 5-15 minutes as needed for anaphylaxis.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment; epinephrine is rapidly metabolized and not renally cleared. |
| Liver impairment | No specific dose adjustment for hepatic impairment; use with caution in severe hepatic disease due to potential increased sensitivity. |
| Pediatric use | Children 15-30 kg: 0.15 mg intramuscularly (anterolateral thigh) every 5-15 minutes as needed; children >30 kg: 0.3 mg intramuscularly every 5-15 minutes as needed. For infants <15 kg, use epinephrine 1 mg/mL solution (0.01 mg/kg) via syringe. |
| Geriatric use | Use standard adult dose (0.3 mg intramuscularly) with caution due to increased risk of adverse cardiovascular effects; monitor for hypertension, tachycardia, and myocardial ischemia. |
| 1st trimester | Limited human data; animal studies show no teratogenicity at clinically relevant doses. Use only if benefit outweighs risk. |
| 2nd trimester | No evidence of fetal harm in animal studies; human data lacking. Caution advised. |
| 3rd trimester | May cause uterine contractions; avoid in third trimester unless necessary for maternal indication. |
Clinical note
Comprehensive clinical and safety monograph for ZURNAI (AUTOINJECTOR) (ZURNAI (AUTOINJECTOR)).
| Placental transfer | Low transfer expected based on high molecular weight and protein binding. |
| Breastfeeding | Unknown if distributed into human milk. Consider benefits of breastfeeding and importance of drug to mother. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Known hypersensitivity to glatiramer acetate or mannitol
| Precautions | Do not use in infected or inflamed injection sites; risk of hypersensitivity reactions; avoid for intraocular injection or venom dispersal. |
| Food/Dietary | No known food interactions with naloxone. Alcohol may worsen CNS depression but does not directly affect naloxone efficacy. |
| Clinical Pearls | Administer Zurnai (naloxone autoinjector) intramuscularly or subcutaneously into the anterolateral thigh; a needle cover automatically retracts after injection. Use in opioid overdose with respiratory depression; may cause acute withdrawal in dependent patients. Monitor for recurrence of respiratory depression due to shorter duration than many opioids; repeated doses may be necessary. Train caregivers on recognition of overdose and proper injection technique; device has voice instructions. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category C: Zurnai (naloxone autoinjector) has not been studied in pregnant women. In animal reproduction studies, naloxone administered during organogenesis at doses up to 100 times the human dose showed no evidence of teratogenicity or fetotoxicity. However, naloxone crosses the placenta and may precipitate opioid withdrawal in the fetus, potentially leading to adverse effects such as preterm labor, fetal distress, or stillbirth. Use during pregnancy only if the potential benefit justifies the risk to the fetus. |
| Fetal Monitoring | Monitor the pregnant patient for signs of opioid withdrawal, including fetal heart rate abnormalities, preterm labor, and changes in fetal movement. Continuous fetal monitoring is recommended after administration of naloxone during pregnancy, especially in opioid-dependent patients. Also monitor maternal vital signs and level of consciousness. |
| Fertility Effects | There are no controlled studies on the effects of naloxone on human fertility. In animal studies, naloxone at high doses did not impair fertility in rats. However, naloxone can interfere with endogenous opioid systems, which may affect reproductive hormone regulation. Opioid withdrawal induced by naloxone may temporarily disrupt menstrual cyclicity or spermatogenesis, but long-term effects on fertility are not well characterized. |
| Patient Advice | Store at room temperature, protect from light, and do not freeze. · Inspect autoinjector for expiration date and clear solution; do not use if discolored or containing particles. · Administer into outer thigh, through clothing if necessary; hold for 5 seconds after injection. · Seek emergency medical help immediately after use, even if the person wakes up. · If the person does not respond or responds and then relapses, give another dose every 2-3 minutes using a new autoinjector. · Inform all household members of the storage location and how to use the device. |